<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01814241</url>
  </required_header>
  <id_info>
    <org_study_id>13-0900</org_study_id>
    <secondary_id>R01AI068074</secondary_id>
    <nct_id>NCT01814241</nct_id>
  </id_info>
  <brief_title>Mechanisms of Desensitization During Peanut Oral Immunotherapy</brief_title>
  <acronym>PnOIT4</acronym>
  <official_title>Mechanisms of Desensitization During Peanut Oral Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to attempt to understand how desensitization works in peanut
      allergic children who are undergoing oral immunotherapy (OIT) to peanut. We want to identify
      the early changes in the desensitization process the immune cells undergo to become
      desensitized to the peanut protein.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peanut allergic children will undergo an oral food challenge (OFC) to 1 gm peanut protein in
      order to accomplish two objectives: (1)to confirm the diagnosis of peanut allergy, and (2) to
      measure the amount of peanut protein it takes to cause an allergic reaction. Each subject
      will then undergo a modified rush phase in which the subject receives 6 doses of peanut
      protein in one day. The build-up phase begins afterward in which the subject's dose of peanut
      protein is increased every 2 weeks for 36 weeks. After the final build-up dose, the subject
      consumes that dose for 2 weeks after which he or she returns to the food allergy center for
      the second food challenge. If the subject successfully consumes this food challenge without
      symptoms, the daily dosing of peanut protein will be stopped and the subject will then
      undergo a third food challenge. If the subject successfully consumes the peanut protein
      during that challenge, he or she will return for a fourth food challenge to peanut.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Who Develop Desensitization</measure>
    <time_frame>40 weeks</time_frame>
    <description>The percentage of peanut allergic subjects who develop desensitization as defined by being able to consume 5000mg of peanut protein during a double blind food challenge after completing a build-up phase of peanut OIT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Maintain Desensitization Once OIT is Stopped</measure>
    <time_frame>4 weeks</time_frame>
    <description>The percentage of subjects who maintain desensitization once the OIT is withdrawn at 1, 2, 3, and 4 week intervals.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in the Wheal Diameter, as Assessed by the Skin Prick Test (SPT) to Peanut</measure>
    <time_frame>44 weeks</time_frame>
    <description>Allergic reactivity of mast cells is assessed by skin prick testing through measurement of the wheal diameter after exposure to peanut. This outcome measure reports the change in skin prick test wheal diameter from baseline through the end of the treatment period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Peanut Specific Immunoglobin E (IgE) From Baseline Until Desensitization Food Challenge</measure>
    <time_frame>44 weeks</time_frame>
    <description>The investigation of mechanistic changes that occur in the immune system over the duration of the study - Peanut specific immunoglobin E (IgE)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Immunoglobin G4 (IgG4) to Peanut From Baseline Until Desensitization Food Challenge</measure>
    <time_frame>44 weeks</time_frame>
    <description>The investigation of mechanistic changes that occur in the immune system dover the duration of the study - Immunoglobin G4 (IgG4) to peanut</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Food Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Open label peanut OIT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label orally ingested peanut flour with maintenance dose of 1450mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Open label peanut OIT</intervention_name>
    <description>Subject will take increasing amounts of peanut protein up to a maximum maintenace dose of 1450mg.</description>
    <arm_group_label>Open label peanut OIT</arm_group_label>
    <other_name>Peanut flour</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 4 to up to 12 years of age of any gender, race, or ethnicity.

          -  Minimum weight 16 kg at the time of enrollment.

          -  Physician diagnosis of peanut allergy OR convincing clinical history of an allergic
             reaction to peanut.

          -  Detectable serum peanut -specific IgE level (CAP-FEIA ≥ 0.35 kU/L) and a positive SPT
             (wheal ≥ 3mm on skin prick test to peanut extract compared to a negative control.)

          -  Allergic reaction to ≤ 1 gm peanut protein during a blinded oral challenge test
             conducted at screening (e.g., a double-blinded, placebo-controlled food challenge
             [DBPCFC]).

          -  Written informed consent from parent/guardian.

          -  Written assent from subject if applicable

          -  Consumption of oat-containing product within 90 days prior to enrollment

        Exclusion Criteria:

          -  History of allergic reaction to peanut consistent with severe anaphylaxis (defined as
             hypotension/shock; or neurologic impairment).

          -  Chronic disease other than asthma, atopic dermatitis, rhinitis requiring therapy;
             e.g., heart disease or diabetes.

          -  Active eosinophilic gastrointestinal disease in the past 2 years

          -  Participation in any interventional study for the treatment of food allergy in the 6
             months prior to visit -1

          -  Inhalant allergen immunotherapy that has not yet reached maintenance dosing.

          -  Asthma defined as moderate or severe persistent by National Asthma Education and
             Prevention Program Expert Panel Guidelines (e.g. asthma that requires more than
             fluticasone 440 mcg or its equivalent daily for adequate control).

          -  Inability to discontinue antihistamines for skin testing, OFC and the initial dose
             escalation.

          -  Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral
             or sublingual) in the 12 months prior to visit -1.

          -  Any systemic therapy which in the judgment of the investigator could be
             immunomodulatory (e.g. rituximab) in the 12 months prior to visit -1, Systemic
             corticosteroid therapy of up to a total of three weeks is allowed.

          -  Use of investigational drug in 90 days prior to visit -1.

          -  Plan to use any investigational drug during the study period.

          -  The presence of any medical condition that the investigator deems incompatible with
             participation in the trial.

          -  Inability to speak English.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wesley Burks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edwin Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <results_first_submitted>January 22, 2017</results_first_submitted>
  <results_first_submitted_qc>January 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2017</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peanut allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open Label Peanut OIT</title>
          <description>Open label orally ingested peanut flour with maintenance dose of 1450mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Peanut OIT</title>
          <description>Open label orally ingested peanut flour with maintenance dose of 1450mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" lower_limit="5.9" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Develop Desensitization</title>
        <description>The percentage of peanut allergic subjects who develop desensitization as defined by being able to consume 5000mg of peanut protein during a double blind food challenge after completing a build-up phase of peanut OIT.</description>
        <time_frame>40 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Peanut OIT</title>
            <description>Open label orally ingested peanut flour with maintenance dose of 1450mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Develop Desensitization</title>
          <description>The percentage of peanut allergic subjects who develop desensitization as defined by being able to consume 5000mg of peanut protein during a double blind food challenge after completing a build-up phase of peanut OIT.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Maintain Desensitization Once OIT is Stopped</title>
        <description>The percentage of subjects who maintain desensitization once the OIT is withdrawn at 1, 2, 3, and 4 week intervals.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Peanut OIT</title>
            <description>Open label orally ingested peanut flour with maintenance dose of 1450mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Maintain Desensitization Once OIT is Stopped</title>
          <description>The percentage of subjects who maintain desensitization once the OIT is withdrawn at 1, 2, 3, and 4 week intervals.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in the Wheal Diameter, as Assessed by the Skin Prick Test (SPT) to Peanut</title>
        <description>Allergic reactivity of mast cells is assessed by skin prick testing through measurement of the wheal diameter after exposure to peanut. This outcome measure reports the change in skin prick test wheal diameter from baseline through the end of the treatment period.</description>
        <time_frame>44 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Peanut OIT</title>
            <description>Open label orally ingested peanut flour with maintenance dose of 1450mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Wheal Diameter, as Assessed by the Skin Prick Test (SPT) to Peanut</title>
          <description>Allergic reactivity of mast cells is assessed by skin prick testing through measurement of the wheal diameter after exposure to peanut. This outcome measure reports the change in skin prick test wheal diameter from baseline through the end of the treatment period.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" lower_limit="-24.5" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Peanut Specific Immunoglobin E (IgE) From Baseline Until Desensitization Food Challenge</title>
        <description>The investigation of mechanistic changes that occur in the immune system over the duration of the study - Peanut specific immunoglobin E (IgE)</description>
        <time_frame>44 weeks</time_frame>
        <population>Blood work was not able to be obtained from 1 of 16 evaluable subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Peanut OIT</title>
            <description>Subject cohort receiving open label orally ingested peanut flour with maintenance dose of 1450mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peanut Specific Immunoglobin E (IgE) From Baseline Until Desensitization Food Challenge</title>
          <description>The investigation of mechanistic changes that occur in the immune system over the duration of the study - Peanut specific immunoglobin E (IgE)</description>
          <population>Blood work was not able to be obtained from 1 of 16 evaluable subjects</population>
          <units>kU/L of peanut-specific IgE</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19" lower_limit="-466" upper_limit="544.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Immunoglobin G4 (IgG4) to Peanut From Baseline Until Desensitization Food Challenge</title>
        <description>The investigation of mechanistic changes that occur in the immune system dover the duration of the study - Immunoglobin G4 (IgG4) to peanut</description>
        <time_frame>44 weeks</time_frame>
        <population>Blood work was not able to be obtained from 1 of 16 evaluable subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Peanut OIT</title>
            <description>Subject cohort receiving open label orally ingested peanut flour with maintenance dose of 1450mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Immunoglobin G4 (IgG4) to Peanut From Baseline Until Desensitization Food Challenge</title>
          <description>The investigation of mechanistic changes that occur in the immune system dover the duration of the study - Immunoglobin G4 (IgG4) to peanut</description>
          <population>Blood work was not able to be obtained from 1 of 16 evaluable subjects</population>
          <units>mg/dL of IgG4</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" lower_limit="0.47" upper_limit="92.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>31 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open Label Peanut OIT</title>
          <description>Open label orally ingested peanut flour with maintenance dose of 1450mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye itch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eye tearing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythematous rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oropharyngeal itching</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Itchy nose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin itch</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lip or eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Edwin Kim, Director of the UNC Food Allergy Initiative</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-843-9087</phone>
      <email>edwinkim@email.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

